Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Patients with Rheumatoid Arthritis on DMARDs (Phase III)
jRCT2080222228Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in rheumatoid arthritis (RA) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in total Sharp score (TSS). Started Sep 2013; status: completed.
02
Drugs
denosumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222228.